Nasal High-Flow in COPD (High-TeC)
Nasal High-Flow Therapy to Treat COPD Exacerbations: a Matter of Monitoring and Controlling Settings?
Sponsor: Albert Schweitzer Hospital
Listed as NCT03564236, this NA trial focuses on COPD Exacerbation and remains actively recruiting participants. Sponsored by Albert Schweitzer Hospital, it has been updated 10 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Jan 2025 — Present [monthly]
Recruiting NA
-
Sep 2024 — Jan 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Dec 2023 — Jul 2024 [monthly]
Recruiting NA
-
Sep 2022 — Dec 2023 [monthly]
Recruiting NA
▶ Show 5 earlier versions
-
Jan 2021 — Sep 2022 [monthly]
Recruiting NA
-
Dec 2020 — Jan 2021 [monthly]
Recruiting NA
-
Mar 2020 — Dec 2020 [monthly]
Recruiting NA
-
Jul 2019 — Mar 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jul 2018 — Jul 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Albert Schweitzer Hospital
- Fisher and Paykel Healthcare
- Marieke Duiverman
- Medisch Spectrum Twente
- Rijnstate Hospital
- Technical University of Twente
- Vivisol
For direct contact, visit the study record on ClinicalTrials.gov .